• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Kim Coghill

Articles by Kim Coghill

AlgoRx's Series C Round Gets $65M For Phase II Compounds

Nov. 1, 2011
By Kim Coghill
AlgoRx Pharmaceuticals Inc. intends to use proceeds from its $65 million Series C financing to bankroll ongoing development of its two lead Phase II drug candidates. (BioWorld Today)
Read More

Biogen, Elan Planning Antegren Filing In MS With One-Year Data

Nov. 1, 2011
By Kim Coghill
Biogen Idec Inc. and partner Elan Corp. plc gained value Wednesday after telling Wall Street they intend to file the Antegren application for multiple sclerosis based on one-year data, as opposed to waiting for the traditional two-year data set to be completed. (BioWorld Today)
Read More

Antigenics Gets FDA Clearance, Resumes Oncophage Enrollment

Nov. 1, 2011
By Kim Coghill
The FDA gave Antigenics Inc. the go-ahead to resume enrollment of two Phase III trials for the personalized cancer vaccine Oncophage, following a 13-week partial clinical hold. (BioWorld Today)
Read More

Medicare Bill Aims To Get Generics To Market Faster

Nov. 1, 2011
By Kim Coghill
WASHINGTON - Medicare legislation poised for a vote in Congress contains language designed to get generics to market faster by closing loopholes in a law that has enabled certain innovator pharmaceutical companies to block generic competition. (BioWorld Today)
Read More

DepoMed Starting Phase III Study Of Cipro Formulation

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More

Gilead Reports Positive Results From Viread, FTC HIV Studies

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More

Ingelheim Starts Phase III Trials Of Non-Peptidic Protease Inhibitor

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More

BioMimetic Licenses PDGF From ZymoGenetics For Bone Diseases

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More

Phase II Patient's Blood Clot Halts IDEC Antibody Trials

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More

Bush’s Prescription Drug Plan Pitched To House Committee

Nov. 1, 2011
By Kim Coghill
No Abstract
Read More
Previous 1 2 3 4 5 6 7 8 9 … 142 143 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe